By Kelsey Kloss
A new review from CreakyJoints provides recommendations for how providers can guide patients who are interested in cannabis for pain treatment.
New study finds drug formularies often have exclusions that could harm your health or cost you more money.
The approval makes Xeljanz the first JAK inhibitor approved to treat ankylosing spondylitis and Rinvoq the second approved for psoriatic arthritis.
New boxed warnings caution about cardiovascular and cancer risks and recommend that people take a TNF inhibitor biologic before trying a JAK. Here’s what this news means for you.
A new study found that white patients are more likely to be prescribed stronger doses of opioids than Black patients within the same health care system, which suggests race plays a role in how doctors manage patients’ pain relief.
A new study suggests that NSAIDs, a common osteoarthritis pain treatment, could be making symptoms worse. But more research is needed.
The medication, used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, already had a boxed warning for blood clots, infection, and certain cancers. Now more research is needed to understand potential additional risks.
The medication helped improve kidney function in people with lupus nephritis significantly compared with those taking a placebo.
Significantly more men than women saw an improvement in their disease activity a year after starting a biologic, but more research is needed to understand why.
A head-to-head study looked at how RA patients who didn’t do well on their first biologic fared when they switched to either upadacitinib (Rinvoq) or abatacept (Orencia).
By Kelsey Kloss
New research sheds more light on the racial health disparities that exist in arthritis treatments.
By Kelsey Kloss
The medication romosozumab may be more effective at boosting hip and spine bone density when it’s given before other kinds of drugs called antiresorptive medications.
By Kelsey Kloss
Researchers say patients should be reassured that these common injections do not appear to cause progression of osteoarthritis.
Rheumatoid arthritis is known to increase the risk of heart disease, but taking biologic medications that help lower inflammation and disease activity can help you stay healthy.
By Susan Jara
Medication changes are par for the course when managing a chronic condition like rheumatoid arthritis. Here’s what to expect if you’re thinking about a change in your RA treatment plan.
Although steroids are known to have serious side effects when used for an extended period, limited attention has been paid to the risks of using these medications for only a few days or weeks.
Cosentyx is the second interleukin-17 drug approved for non-radiographic axial spondyloarthritis, which is adding to treatment options for patients with this type of inflammatory arthritis.
Formerly prescription-only, the NSAID Voltaren gel will now be sold over the counter. Here’s what it means if you have arthritis and use this cream for pain relief.
A small animal study published earlier this year suggests that timing of non-steroidal anti-inflammatory medication can affect their effectiveness.
A new study found that many patients who tapered their meds wound up flaring.
Taltz, approved last year for ankylosing spondylitis, inhibits an immune system protein called IL-17 that can lead to inflammation.
For many patients, side effects worsened right after the MTX dose.
Some studies have suggested that more patients would benefit from starting with a combination of methotrexate and a TNF inhibitor from the time of an RA diagnosis, but new research is casting doubt on that idea.
Initially used to treat seizures, anticonvulsant medications have become more widely used to treat certain types of chronic pain, such as fibromyalgia.
The disease-modifying drug could help improve the effectiveness of biologic medications in axSpA.
According to a study of insurance claims data, about 20 percent of anti-TNF drug prescriptions filled were for brand-name infliximab (Remicade) while less than 1 percent were for an infliximab biosimilar.
RA patients were apt to receive a biologic drug sooner if they lived in an urban area closer to a prescriber.
By CreakyStaff
Only about one-third of RA patients in high disease activity were offered a treatment change at their rheumatologist visit, according to a recent study in the ArthritisPower research registry.
By Tina Donvito
Find out if you should give a TENS device a try to relieve your pain.
By